We narrowed to 5,890 results for: SUP

1. pDONR221-SLC25A15_STOP

   Plasmid

   #161133

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC25A15 (SLC25A15 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   June 21, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

2. pDONR221_SLC6A4

   Plasmid

   #132172

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC6A4 (SLC6A4 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Oct. 25, 2019

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

3. pDONR221-SLC11A1_STOP

   Plasmid

   #161117

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC11A1 (SLC11A1 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   June 21, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

4. pDONR221-SLC17A6_STOP

   Plasmid

   #161114

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC17A6 (SLC17A6 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   June 21, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

5. pDule-3-nitroTyrosine (A7)

   Plasmid

   #174078

   Purpose

   Plasmid for incorporating the non-canonical amino acid 3-nitroTyrosine with the third generation Mj 3NY (A7) synthetase and cognate amber suppressing tRNA in Ecoli.

   Depositor

   Ryan Mehl

   Article

   Beyer et al J Mol Biol. 2020 Jul 24;432(16):4690-470

   Insert

   3-nitroTyrosine tRNA synthetase and cognate amber suppressing tRNA derived from M. jannaschii Tyrosine synthetase/tRNA system
   

   Use

   Tags

   Expression

   Bacterial

   Mutation

   Y32H H70T D158H I159A L162R

   Promoter

   GlnRS (constitutive)

   Available since

   Oct. 20, 2021

   Availability

   Academic Institutions and Nonprofits only

   

   Enlarge

6. pDONR221_SLC25A37

   Plasmid

   #132041

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC25A37 (SLC25A37 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Nov. 4, 2019

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

7. pDONR221-SLC11A2_STOP

   Plasmid

   #161050

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC11A2 (SLC11A2 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   June 21, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

8. pDONR221_SLC34A1

   Plasmid

   #132100

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC34A1 (SLC34A1 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   Nov. 21, 2019

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

9. pDONR221-SLC25A2_STOP

   Plasmid

   #161181

   Purpose

   Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

   Depositor

   Giulio Superti-Furga, RESOLUTE Consortium

   Article

   Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

   Insert

   SLC25A2 (SLC25A2 Human)
   

   Use

   Tags

   Expression

   Mammalian

   Mutation

   Promoter

   Available since

   June 21, 2021

   Availability

   Industry, Academic Institutions, and Nonprofits

   

   Enlarge

10. pDONR221-SLC25A11_STOP

    Plasmid

    #161192

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC25A11 (SLC25A11 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    June 21, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

11. pDONR221-SLC22A8_STOP

    Plasmid

    #161155

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC22A8 (SLC22A8 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    June 21, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

12. pDONR221-SLC12A6_STOP

    Plasmid

    #161122

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC12A6 (SLC12A6 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    June 21, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

13. pDONR221-SLC7A6_STOP

    Plasmid

    #161375

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC7A6 (SLC7A6 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    Sept. 15, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

14. pDONR221-SLC37A3_STOP

    Plasmid

    #161273

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC37A3 (SLC37A3 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    Sept. 15, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

15. pDONR221-SLC28A3_STOP

    Plasmid

    #161317

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC28A3 (SLC28A3 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    Oct. 15, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

16. pDONR221-SLC28A2_STOP

    Plasmid

    #161234

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC28A2 (SLC28A2 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    Sept. 15, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

17. pDONR221-SLC10A1_STOP

    Plasmid

    #161073

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC10A1 (SLC10A1 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    June 21, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

18. pDONR221_SLCO1B3

    Plasmid

    #132200

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLCO1B3 (SLCO1B3 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    Oct. 28, 2019

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

19. pDONR221-SLC16A9_STOP

    Plasmid

    #161042

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    SLC16A9 (SLC16A9 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    June 21, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge

20. pDONR221-UCP1_STOP

    Plasmid

    #161440

    Purpose

    Gateway entry clone with codon-optimized ORF sequence for subcloning into custom expression vectors. Contains a STOP codon at the end of the codon-optimized ORF sequence.

    Depositor

    Giulio Superti-Furga, RESOLUTE Consortium

    Article

    Superti-Furga et al Nat Rev Drug Discov. 2020 Jul;19(7):429-

    Insert

    UCP1 (UCP1 Human)
    

    Use

    Tags

    Expression

    Mammalian

    Mutation

    Promoter

    Available since

    Sept. 15, 2021

    Availability

    Industry, Academic Institutions, and Nonprofits

    

    Enlarge